A tale of two yeasts: Saccharomyces cerevisiae as a therapeutic against candidiasis

Duncan Wilson

Research output: Contribution to journalEditorialpeer-review

5 Citations (Scopus)
6 Downloads (Pure)


Normally a benign commensal colonizer of mucosal surfaces such as the gastrointestinal tract, Candida albicans is also one of the most common fungal pathogens of humans, responsible for both superficial as well as life-threatening invasive infections. Arguably the commonest type of infection caused by C. albicans is vulvovaginal candidiasis (VVC), as it affects 75% of women of childbearing age.1 Sobel JD. Vulvovaginal candidosis. Lancet 2007; 369:1961-71; PMID:17560449; http://dx.doi.org 10.1016/S0140-6736(07)60917-9[CrossRef], [PubMed], [Web of Science ®] And unlike many other manifestations of candidiasis, which are associated with particular immune deficiencies, VVC frequently occurs in otherwise healthy women.
Original languageEnglish
Pages (from-to)15-17
Number of pages3
Issue number1
Early online date31 Aug 2016
Publication statusPublished - 2017


  • Candida albicans
  • Saccharomyces cerevisiae
  • vulvovaginal candidiasis


Dive into the research topics of 'A tale of two yeasts: <i> Saccharomyces cerevisiae</i> as a therapeutic against candidiasis'. Together they form a unique fingerprint.

Cite this